Activation of the NF-κB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKα

被引:23
作者
Malinge, S.
Monni, R.
Bernard, O.
Penard-Lacronique, V.
机构
[1] Hop Necker Enfants Malad, F-75743 Paris, France
[2] INSERM, U528, Sect Rech, Inst Curie, Paris, France
关键词
D O I
10.1038/sj.onc.1209390
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Abnormal activation of tyrosine kinases and of signaling pathways they control plays a critical role in the neoplastic process of human hematopoietic malignancy. The nuclear factor-kappa B (NF-kappa B) pathway is one of the signalings activated by the TEL-Jak2 and TEL-Abl oncoproteins and required for their antiapoptotic activity. To define the signal relay responsible for this activation, we used mouse embryonic fibroblast (MEF) cells and observed that TEL-Jak2- and TEL-Abl-mediated NF-kappa B induction was abolished in cells lacking the I kappa B kinase (IKK)alpha but not in IKK beta(-/-) cells. Similar observations were performed with oncogenic forms of the FMS-like tyrosine kinase 3 (Flt-3) involved in the pathogenesis of one-third of acute myeloid leukemias. Rescue of TEL-Jak2-mediated NF-kappa B activation was obtained with a kinase-proficient form of IKK alpha in IKK alpha(-/-) MEF. Hematopoietic cells transformed by TEL-Jak2 and TEL-Abl showed sustained IKK alpha activity without promotion of NF-kappa B2/p100 processing, generally associated to IKK alpha functions. Furthermore, IAP1, IAP2 and XIAP, which are central regulators of the NF-kappa B-mediated survival pathway, were highly expressed in cells transformed by these oncoproteins. Our results indicate that these oncogenic tyrosine kinases preferentially use an IKK alpha-dependent mechanism to induce a persistent NF-kappa B activity and allow the production of antiapoptotic effectors that participate to their leukemogenic properties.
引用
收藏
页码:3589 / 3597
页数:9
相关论文
共 67 条
[1]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[2]   Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts [J].
Baumgartner, B ;
Weber, M ;
Quirling, M ;
Fischer, C ;
Page, S ;
Adam, M ;
von Schilling, C ;
Waterhouse, C ;
Schmid, C ;
Neumeier, D ;
Brand, K .
LEUKEMIA, 2002, 16 (10) :2062-2071
[3]   Constitutive activation of NF-κB and T-cell leukemia/lymphoma in Notch3 transgenic mice [J].
Bellavia, D ;
Campese, AF ;
Alesse, E ;
Vacca, A ;
Felli, MP ;
Balestri, A ;
Stoppacciaro, A ;
Tiveron, C ;
Tatangelo, L ;
Giovarelli, M ;
Gaetano, C ;
Ruco, L ;
Hoffman, ES ;
Hayday, AC ;
Lendahl, U ;
Frati, L ;
Gulino, A ;
Screpanti, I .
EMBO JOURNAL, 2000, 19 (13) :3337-3348
[4]   Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-κB activation [J].
Béraud, C ;
Henzel, WJ ;
Baeuerle, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (02) :429-434
[5]   Evidence for a role of NF-κB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor β fusion protein [J].
Besançon, F ;
Atfi, A ;
Gespach, C ;
Cayre, YE ;
Bourgeade, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8081-8086
[6]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[7]   Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells [J].
Davis, RE ;
Brown, KD ;
Siebenlist, U ;
Staudt, LM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (12) :1861-1874
[8]   The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators [J].
Dechend, R ;
Hirano, F ;
Lehmann, K ;
Heissmeyer, V ;
Ansieau, S ;
Wulczyn, FG ;
Scheidereit, C ;
Leutz, A .
ONCOGENE, 1999, 18 (22) :3316-3323
[9]   β-catenin interacts with and inhibits NF-κB in human colon and breast cancer [J].
Deng, JO ;
Miller, SA ;
Wang, HY ;
Xia, WY ;
Wen, Y ;
Zhou, BHP ;
Li, Y ;
Lin, SY ;
Hung, MC .
CANCER CELL, 2002, 2 (04) :323-334
[10]   Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades [J].
Digicaylioglu, M ;
Lipton, SA .
NATURE, 2001, 412 (6847) :641-647